Edition:
United States

Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

33.25USD
1:34pm EDT
Change (% chg)

$0.07 (+0.21%)
Prev Close
$33.18
Open
$33.19
Day's High
$33.26
Day's Low
$33.18
Volume
833,554
Avg. Vol
3,498,482
52-wk High
$35.40
52-wk Low
$17.61

AKRX.O

Chart for AKRX.O

About

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $4,132.74
Shares Outstanding(Mil.): 124.56
Dividend: --
Yield (%): --

Financials

  AKRX.O Industry Sector
P/E (TTM): 22.67 14.35 17.42
EPS (TTM): 1.46 -- --
ROI: 10.44 -7.29 -5.45
ROE: 23.86 -6.80 -4.73

REFILE-Fresenius vows to take breather after three deals

FRANKFURT, May 12 The head of German healthcare group Fresenius SE said he would abstain from the takeover market for now, after striking three deals worth billions of euros in total since taking over less than a year ago.

May 12 2017

Fresenius ups guidance on growth at generic drugs unit

FRANKFURT German healthcare group Fresenius on Wednesday toned up its earnings guidance for the year as demand for recently launched generic infusion drugs continued to grow at higher-than-expected rates.

May 03 2017

Fresenius ups FY guidance on growth at generic drugs unit

FRANKFURT, May 3 German healthcare group Fresenius SE & Co KGaA on Wednesday lifted its guidance on strong demand in the United States for its generic infusion drugs.

May 03 2017

Deals of the day-Mergers and acquisitions

April 25 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

Apr 25 2017

Fresenius picks up M&A pace with Akorn, Merck KGaA deals

FRANKFURT German healthcare group Fresenius SE & Co KGaA has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros) and the biosimilars arm of Germany's Merck KGaA.

Apr 25 2017

UPDATE 2-Fresenius picks up M&A pace with Akorn, Merck KGaA deals

* Fresenius shares up almost 1 percent (Adds advisers, shares, background, CEO, analyst comments)

Apr 25 2017

German stocks - Factors to watch on April 25

FRANKFURT, April 25 The DAX top-30 index looked set to open 0.3 percent higher on Tuesday, according to premarket data from brokerage Lang & Schwarz at 0625 GMT.

Apr 25 2017

BRIEF-Akorn deal to pay Fresenius Kabi AG termination fee of $129 mln under specified circumstances

* Akorn - deal with Fresenius Kabi provides under specified circumstances, co to be required to pay Fresenius Kabi AG termination fee of $129 million Source text: (http://bit.ly/2oEMWQV) Further company coverage:

Apr 24 2017

Fresenius snaps up Akorn, Merck KGaA's biosimilars in separate deals

FRANKFURT, April 24 Acquisitive German healthcare conglomerate Fresenius SE & Co KGaA revved up its deals pace by acquiring U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros), and in a separate deal, the biosimilars unit of German peer Merck KGaA .

Apr 24 2017

Exclusive: Fresenius nears deal to acquire Akorn - sources

German healthcare conglomerate Fresenius SE & Co KGaA is close to acquiring generic drugmaker Akorn Inc in an all-cash deal valuing the company at more than $4 billion, people familiar with the matter said on Monday.

Apr 24 2017

More From Around the Web

Earnings vs. Estimates